Variable | All patients (n = 61) |
---|---|
Median age | 64 (41–81) |
Sex | |
Male | 35 (57%) |
Female | 26 (43%) |
Median tumor size (mm) | 37 (11–100) |
Median CA 19-9 levels | 385.5 (5–102041) |
CA 19-9 | |
< 37U/mL | 13 (21%) |
≥ 37U/mL | 47 (77%) |
Missing data | 1 (2%) |
Tumor location | |
Pancreas head | 34 (56%) |
Pancreas body | 4 (7%) |
Pancreas tail | 13 (21%) |
Multiple | 10 (16%) |
T-stage | |
T2 | 11 (18%) |
T3 | 15 (25%) |
T4 | 25 (41%) |
TX | 2 (3%) |
Missing data | 8 (13%) |
Clinical stage | |
Stage III | 6 (10%) |
Stage IV | 55 (90%) |
Metastatic location | |
Liver | 25 (41%) |
Lung | 4 (7%) |
Multiple | 16 (26%) |
Other | 6 (10%) |
Missing data | 10 (16%) |
N-stage | |
N0 | 14 (23%) |
N1 | 25 (41%) |
NX | 21 (34%) |
Missing data | 1 (2%) |
ECOG status | |
0 | 13 (21%) |
1 | 34 (56%) |
2 | 10 (16%) |
Missing data | 4 (7%) |
First-line treatment | |
Gemcitabine | 6 (10%) |
FOLFIRINOX | 30 (49%) |
Nab-Paclitaxel + | 25 (41%) |
Gemcitabine | |
Second-line treatment | |
Yes | 17 (28%) |
No | 44 (72%) |
Prior anti-cancer surgery | |
Yes | 9 (15%) |
No | 51 (84%) |
Missing data | 1 (2%) |